PMID- 10506406
OWN - NLM
STAT- MEDLINE
DCOM- 19991228
LR  - 20190728
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 17 Suppl 2
DP  - 1999 Oct 1
TI  - Glycoprotein conjugate vaccines.
PG  - S28-36
AB  - The polysaccharide capsule which surrounds bacterial species like Haemophilus 
      influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Salmonella typhi, 
      is a potent virulence factor. It protects the bacterium from phagocytosis, but 
      capsule specific antibodies plus complement binding to the capsule opsonise the 
      organism for phagocytosis and elimination. Purified capsules elicit T-independent 
      antibody responses without a memory function, and are often poorly immunogenic in 
      infants where much of invasive H. influenzae type b (Hib) and pneumococcal 
      infection is seen. Covalent linkage of the polysaccharide, or fractions thereof, 
      to immunogenic carrier proteins creates glycoconjugates which are T-dependent 
      antigens and which prime for boosting either with the glycoconjugate or the 
      capsular polysaccharide; During the 1990s, four Hib glycoconjugate vaccines have 
      been introduced and in countries that have vaccinated the majority of children, 
      the success has been stunning. In countries with very high immunization coverage 
      the disease has been virtually eliminated and, to a decline of over 95% in 
      countries with slightly lower vaccine rates. Worldwide use of Hib glycoconjugate 
      vaccines offers the possibility of elimination of invasive Hib disease. 
      Pneumococcal (11 serotypes with coverage of approximately 85% of invasive 
      disease) and meningococcal (A, C, W 135, Y but not B) glycoconjugates are in 
      pre-registration phases and offer the prospect of being as successful as the Hib 
      glycoconjugates.
FAU - Lindberg, A A
AU  - Lindberg AA
AD  - Pasteur Merieux Connaught, 1541 Avenue Marcel Merieux 69280, Marcy l'Etoile, 
      France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Glycoproteins)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
MH  - Glycoproteins/*immunology
MH  - Humans
MH  - Neisseria meningitidis/immunology
MH  - Streptococcus pneumoniae/immunology
MH  - Treatment Outcome
MH  - *Vaccines, Conjugate
MH  - Virulence
RF  - 79
EDAT- 1999/10/03 00:00
MHDA- 1999/10/03 00:01
CRDT- 1999/10/03 00:00
PHST- 1999/10/03 00:00 [pubmed]
PHST- 1999/10/03 00:01 [medline]
PHST- 1999/10/03 00:00 [entrez]
AID - S0264410X99002327 [pii]
AID - 10.1016/s0264-410x(99)00232-7 [doi]
PST - ppublish
SO  - Vaccine. 1999 Oct 1;17 Suppl 2:S28-36. doi: 10.1016/s0264-410x(99)00232-7.